Literature DB >> 2556864

Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors.

B M Kacinski1, D Carter, E I Kohorn, K Mittal, R S Bloodgood, J Donahue, C A Kramer, D Fischer, R Edwards, S K Chambers.   

Abstract

Six-micron paraffin sections of paraformaldehyde-fixed specimens of 24 ovarian benign and neoplastic specimens were assayed for tumor cell-specific oncogene expression by a sensitive, quantitative in situ hybridization technique with probes for 17 oncogenes, beta-actin, and E. coli beta-lactamase. In the benign, borderline, and invasive adenocarcinomas, multiple oncogenes, including neu, fes, fms, Ha-ras, trk, c-myc, fos, and PDGF-A chains, were expressed at significant levels relative to a housekeeping gene (beta-actin). In the mixed-Mullerian tumors, a rather different pattern of oncogene expression was observed, characterized primarily by expression of sis (PDGF-B chain). For the adenocarcinomas, statistical analysis demonstrated that expression of several genes (fms, neu, PDGF-A) was closely linked to others (c-fos, c-myc) known to have important roles in the control of cell proliferation, but only one gene, fms, correlated very strongly with clinicopathologic features (high FIGO histologic grade and high FIGO clinical stage) predictive of aggressive clinical behavior and poor outcome. The authors discuss the role that tumor epithelial cell expression of the fms gene product might play in the auto- and paracrine control of growth and dissemination of ovarian adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556864      PMCID: PMC2589084     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  58 in total

1.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

2.  Induction of c-fos gene and protein by growth factors precedes activation of c-myc.

Authors:  R Müller; R Bravo; J Burckhardt; T Curran
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

3.  Advanced ovarian cancer: correlation of histologic grade with response to therapy and survival.

Authors:  R F Ozols; A J Garvin; J Costa; R M Simon; R C Young
Journal:  Cancer       Date:  1980-02       Impact factor: 6.860

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarcinoma cell lines.

Authors:  C W Rettenmier; R Sacca; W L Furman; M F Roussel; J T Holt; A W Nienhuis; E R Stanley; C J Sherr
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

6.  A monoclonal antibody reactive with an activated ras protein expressing valine at position 12.

Authors:  W P Carney; P Hamer; D Petit; H Wolfe; G Cooper; M Lefebvre; H Rabin
Journal:  J Cell Biochem       Date:  1986       Impact factor: 4.429

7.  High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas.

Authors:  B M Kacinski; D Carter; K Mittal; E I Kohorn; R S Bloodgood; J Donahue; L Donofrio; R Edwards; P E Schwartz; J T Chambers
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-10       Impact factor: 7.038

8.  L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.

Authors:  M M Nau; B J Brooks; J Battey; E Sausville; A F Gazdar; I R Kirsch; O W McBride; V Bertness; G F Hollis; J D Minna
Journal:  Nature       Date:  1985 Nov 7-13       Impact factor: 49.962

Review 9.  Molecular mechanisms of oncogenesis.

Authors:  T A Seemayer; W K Cavenee
Journal:  Lab Invest       Date:  1989-05       Impact factor: 5.662

10.  Regulation of colony-stimulating factor 1 during pregnancy.

Authors:  A Bartocci; J W Pollard; E R Stanley
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

View more
  6 in total

1.  Cytogenetic, morphologic and oncogene analysis of a cell line derived from a heterologous mixed mullerian tumor of the ovary.

Authors:  J L Becker; P R Papenhausen; R H Widen
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-05       Impact factor: 2.416

2.  Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1.

Authors:  B M Kacinski; D Carter; K Mittal; L D Yee; K A Scata; L Donofrio; S K Chambers; K I Wang; T Yang-Feng; L R Rohrschneider
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

3.  Effects of alcohol on c-Myc protein in the brain.

Authors:  Tunde Akinyeke; Sydney J Weber; April T Davenport; Erich J Baker; James B Daunais; Jacob Raber
Journal:  Behav Brain Res       Date:  2016-11-08       Impact factor: 3.332

4.  Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer.

Authors:  Anca Maria Cimpean; Ionut Marcel Cobec; Raluca Amalia Ceaușu; Roxana Popescu; Anca Tudor; Marius Raica
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

5.  Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines.

Authors:  B L King; D Carter; H G Foellmer; B M Kacinski
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

6.  Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma.

Authors:  D M Eccles; L Brett; A Lessells; L Gruber; D Lane; C M Steel; R C Leonard
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.